Problems and prospects of sugar beet cultivation in Kazakhstan (Changed title according to reviewers' comments)

Received: May 21st, 2023 ; Accepted: August 5th, 2023 ; Published: October 24th, 2023Purpose - to ensure the food security of Kazakhstan, domestic sugar industry should aim at a significant reduction in import dependence and transition to self-sufficiency. The share of domestic sugar from sugar beet in Kazakhstan is 7%. Design/methodology/approach - review indicating the main problems in the sugar beet production in Kazakhstan for the purpose of reimagining the domestic sugar beet industry to reduce dependence on sugar import. We analyzed the dynamics of sugar beet cultivation in Kazakhstan over the past 20 years and detected a sharp reduction in the sugar beet production. Findings - we have identified 10 problems in sugar beet production in Kazakhstan and determined the necessary targeted solutions. We consider the main direction to be the development of scientific methodology for sugar beet production (breeding of new highly productive disease-resistant cultivars, improvement of sugar beet protection system, efficient crop rotation). The most notable problems included in this paper are small-scale marketability of sugar beet farms, infectious diseases of sugar beet, water supply shortages, use of outdated agricultural technologies, high cost of imported sugar beet seeds. Originality/value - The present paper includes a full analysis of current problems in sugar beet production in Kazakhstan

Financial controlling as a progressive form of internal control of the enterprise

В статті розглянуто теоретико-концептуальні основи проведення фінансового контролінгу на підприємстві. Виділено основні класифікаційні ознаки загроз підприємству, які покликаний функціонально вирішити саме фінансовий контролінг. Обґрунтовано основні чинники підвищення ефективності та рентабельності підприємства за умови чіткого дотримання правил проведення і системності фінансового контролінгу.The article deals with theoretical and conceptual bases of carrying out of financial control in the enterprise. The main classification signs of threats to the enterprise, which are designed to functionally solve financial conglomeration, are highlighted. The main factors of increase of efficiency and profitability of the enterprise are grounded under the condition of strict adherence to rules of conduction and systematic financial control

Contradiction and change in state socialism

No abstract available

M. BOVIS BCG-1 (RUSSIA) SUB-STRAIN GENOME STABILITY INVESTIGATION WITHIN THE ENTIRE PRODUCTION PROCESS

Aim. The aim of the current study was to analyze the genome structure of the M. bovis BCG-1 (Russia) sub-strain, used for the vaccine production, as well as its genome stability within the entire production process. Materials and methods. Whole genome sequencing and M. bovis BCG-1 (Russia) working seed lot and for the last production passage of the sub-strain cultivation from a number of the vaccine batches. Additionally, VNTR sequences of 24 locus analyses, RD patterns comparison, as well as spoligotyping were performed. Results. The whole genome sequence of the M. bovis BCG-1 (Russia) working seed lot was assembled, annotated and deposited to GenBank. On the basis of DU2- and RD-regions analyzes M. bovis BCG-1 (Russia) sub-strain was confirmed to be belonged to BCG Russia strains of DU2-I group. Whole genome sequencing followed by comparative analysis of RD patterns and SNPs confirmed the stability of the vaccine sub-strain genome from the working seed lot to a number of the vaccine batches obtained within the two-years period. VNTR profile and spoligopattern exactly matched the M. bovis BCG-1 (Russia). Conclusion. Thus the M. bovis BCG-1 (Russia) sub-strain genome identity and stability have been studied and demonstrated. The obtained result confirmed the vaccine production process consistency

A non-interventional, prospective, multicenter study for evaluation of the use of the herbal medicinal product Canephron® N in the pediatric outpatient population in Russia

Abstract Background A herbal medicinal product (HMP) with centaury, lovage, and rosemary as active ingredients (brand name: Canephron® N) has been widely used for treatment and prevention of urinary tract infections (UTIs) and other urinary system disorders. Non-clinical in vitro and in vivo data indicate its diuretic, spasmolytic, anti-inflammatory, antioxidative and analgesic effects. The purpose of this non-interventional, prospective, multicenter study was to collect data on the use of the HMP in the Russian pediatric outpatient population. Results In total, 636 outpatients aged 1–17 years were enrolled. Of these, 634 received at least one dose of the HMP and were included in the safety set, which was used for analysis. 61 patients were 12–23 months, 227 were 2–5 years, 234 were 6–11 years and 112 were 12–17 years of age. The oral solution of the HMP was prescribed in 66.4%, and tablets (dragées) in 33.6% of the patients. For 48% of the patients the HMP was prescribed to treat an acute or chronic disease, 25% of the patients received it for prophylaxis, and 27% for both. More than half of the patients (53%) received the HMP as monotherapy. Main treatment indications were UTIs (34.1%) and pyelonephritis (30.0%). The proportion of UTIs was the highest within the youngest age group (51%), while the proportion of different cystitis forms increased in patients older than 2 years. Relevant proportions of different nephritis forms and urolithiasis were only observed in patients aged 12–17 years. Forms of cystitis were more frequent in female than in male patients (15% vs. 1%), while forms of nephritis, urolithiasis, and dysmetabolic nephropathy / crystalluria were more frequent in male patients. At the end of the observational period, 20% of the patients were reported as recovered from their disease, and 65% were reported to show improvements. For 91% of all patients with HMP monotherapy the investigators evaluated the effectiveness of the HMP as ‘good’ or ‘very good’. Nearly all patients (99%) evaluated the tolerability as ‘good‘or ‘very good‘. Five adverse drug reactions were observed. Conclusions The treatment of children aged 1–17 years with the HMP is safe and well tolerated. The study results support the use of the HMP for treatment and prophylaxis of urinary system diseases